Crinone® (progesterone gel) is Juniper Pharmaceuticals’ most successful product to date and our single largest revenue source. It is approved for sale by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide, and by Allergan, Inc. in the U.S.
Crinone is formulated using the BDS technology (bioadhesive delivery system) in the vaginal gel form. The principles of bioadhesion enable Crinone to deliver its active drug, progesterone, in a controlled and sustained manner.
For more information on Crinone 8%, please visit Allergan’s product website crinoneusa.com.
For Crinone patient support, or to report an adverse event in the U.S., please contact Allergan as follows:
To report adverse events and product complaints for Crinone sold outside the U.S., including OneCrinone® in Japan, please contact Merck KGaA, Darmstadt, Germany; contact details are listed in the leaflet or labelling accompanying the product.
Adverse events may also be reported directly to the FDA through MedWatch at http://www.fda.gov/Safety/MedWatch/default.htm.
Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.
OneCrinone® is a registered trademark of Merck KGaA, Darmstadt, Germany.